Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2019
At a glance
- Drugs CV 8102 (Primary)
- Indications Adenoid cystic carcinoma; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors CureVac
- 07 Nov 2018 According to a CureVac's media release, preliminary data will be presented at the 2018 Society of Immunotherapy of Cancers (SITC) 33rd Annual Meeting.
- 28 Aug 2018 Planned number of patients changed from 104 to 146.
- 27 Sep 2017 Status changed from not yet recruiting to recruiting.